Milestone Pharmaceuticals MIST 深 沪
等待开盘 09-16 09:30:00 美东时间
1.97
+0.010
+0.51%
华盛通- 最 高2.05
- 今 开1.99
- 成交量 106.84万股
- 最 低 1.93
- 昨 收 1.96
- 总市值 1.67亿
- 52周最高 2.75
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.6254
- 委 比 19.06%
- 总股本 8499.43万
- 历史最高 27.95
- 量 比 0.71
- 振 幅 6.12%
- 历史最低 0.6254
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多异次元高颜本的战力天花板 COLORFIRE MEOW 橘宝R16 Ultra评测
【ZOL中关村在线原创评测】如何在竞争惨烈的游戏本市场立足，七彩虹旗下的COLORFIRE走出了一条不同，但备受年轻人追捧的路。今天我们拿到了定位高端的COL...
09-12 14:07
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
FDA Announces Discontinuation Of Manufacture Of DYMISTA Nasal Spray, 137 mcg; 50 mcg A Registered Trademark Of Meda Pharmaceuticals Inc., A Viatris Company
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202236s021lbl.pdf
09-04 23:37
150亿元日本TCG市场，万代等五大企业玩出哪些IP新花样？| 文创潮
（来源：三文娱） 万代、多美、Bushiroad、Konami、宝可梦，各大厂商积极发展热门IP联动，希望扩展用户圈层 作者：トトロ 六月份，日本玩具协会发布...
08-21 07:05
Milestone® Pharmaceuticals to Present at Upcoming Conferences
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joe Oliveto will participate in one-on-one meetings at the Wells Fargo Healthcare Conference (September 3-5, Boston) and provide a corporate update at the H.C. Wainwright 27th Annual Global Investment Conference (September 8-10, New York). The presentation by H.C. Wainwright will be available live on September 9 at 12:00 PM EDT via webcast and a replay will be accessible for 90 days...
08-19 12:00
Milestone Pharmaceuticals Q2 EPS $(0.20) Misses $(0.17) Estimate
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 15.61 percent. This is a 42.86 percent decrease over losses of $(0.14) per
08-12 19:15
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals reported its second-quarter 2025 financial results and updates, noting the FDA accepted the company's response to the CRL for CARDAMYST™ (etripamil) nasal spray, setting a new PDUFA target date of December 13, 2025. The company completed a public offering, raising up to $170 million, and extended a $75 million royalty agreement with RTW through December 2025. Financials showed cash of $43.4 million as of June 30, 2025, a...
08-12 11:05
Why Is Milestone Pharmaceuticals Stock Plunging On Friday?
FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support potential PSVT treatment launch.
07-12 00:22
Milestone Pharmaceuticals plunges after pricing $52.5M offering
Milestone Pharmaceuticals (NASDAQ:MIST) shares fell nearly 38% on Friday after the company priced an offering to raise approximately $52.5 million. The offering includes 31.5 million common shares wit...
07-11 22:41
Milestone Pharma Prices $52.5M Equity Offering With Warrants; Offering Is Expected To Close On Or About July 14, 2025
Milestone® Pharmaceuticals Inc. ("Milestone") (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its
07-11 21:34
